Phase 3 Recruiting NIH
This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061977
Sites in Alabama: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Phase 2, Phase 3 Recruiting Industry
Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizum…
Sponsor: Bicara Therapeutics
NCT ID: NCT06788990
Sites in Alabama: - Site # 0137 — Birmingham, Alabama
Phase 3 Recruiting Industry
The goal of this study is to understand whether CRB-701, a targeted form of chemotherapy called an anti-body drug conjugate, will work as a treatment for oropharyngeal (throat, tonsil) cancer. In patients who have already received platinum…
Sponsor: Corbus Pharmaceuticals Inc.
NCT ID: NCT07768189
Sites in Alabama: - Clearview Cancer Institute — Huntsville, Alabama
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07216703
Sites in Alabama: - University of Alabama- Birmingham ( Site 5015) — Birmingham, Alabama
Phase 3 Recruiting Industry
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progres…
Sponsor: AstraZeneca
NCT ID: NCT06079671
Sites in Alabama: - Research Site — Birmingham, Alabama
Phase 2 Recruiting NIH
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04671667
Sites in Alabama: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Phase 2 Recruiting NIH
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in Alabama: - Children's Hospital of Alabama — Birmingham, Alabama
Phase 2 Recruiting Industry
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it…
Sponsor: Bayer
NCT ID: NCT06760819
Sites in Alabama: - UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital — Birmingham, Alabama
Phase 2 Recruiting Academic/Other
This phase II trial tests how well pB1-11 and human papillomavirus tumor antigen (TA-HPV) vaccines in combination with pembrolizumab work in treating patients with oropharyngeal cancer that has come back (recurrent) or that has spread from…
Sponsor: Michael K. Gibson
NCT ID: NCT05799144
Sites in Alabama: - University of Alabama Birmingham — Birmingham, Alabama
Phase 1 Recruiting Industry
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
Sponsor: SystImmune Inc.
NCT ID: NCT06293898
Sites in Alabama: - University of Alabama Birmingham — Birmingham, Alabama
Phase 1 Recruiting Industry
This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for part…
Sponsor: Johnson & Johnson Enterprise Innovation Inc.
NCT ID: NCT07219212
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Phase 1 Recruiting Academic/Other
A Feasibility Trial of PVX7 vaccine in advanced cervical cancer patients who have completed primary definitive therapy.
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT06315257
Sites in Alabama: - The University of Alabama at Birmingham — Birmingham, Alabama
Phase 1 Recruiting Academic/Other
Phase I clinical trial to assess safety of pNGVL4aCRTE6E7L2 DNA and TA-CIN protein vaccinations, and to seek the appropriate dose of the pNGVL4aCRTE6E7L2 DNA vaccine
Sponsor: University of Alabama at Birmingham
NCT ID: NCT03913117
Sites in Alabama: - UAB | The University of Alabama at Birmingham — Birmingham, Alabama
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Alabama: - Massive Bio SYNERGY-AI site — Birmingham, Alabama
- Massive Bio SYNERGY-AI site — Mobile, Alabama
Recruiting Industry
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinica…
Sponsor: Guardant Health, Inc.
NCT ID: NCT05059444
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
NA Recruiting NIH
This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention. HPV is a comm…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07281430
Sites in Alabama: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Recruiting Industry
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have n…
Sponsor: AstraZeneca
NCT ID: NCT07124000
Sites in Alabama: - Research Site — Birmingham, Alabama
NA Recruiting Industry
This is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for locally advanced cervical cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with th…
Sponsor: Varian, a Siemens Healthineers Company
NCT ID: NCT05197881
Sites in Alabama: - University of Alabama Birmingham — Burmingham, Alabama
NA Recruiting Academic/Other
The purpose of the study is to find out if a self-administered (by the patient) Papanicolaou (Pap) smear is as accurate as a traditional Pap smear administered by a healthcare provider.
Sponsor: University of Alabama at Birmingham
NCT ID: NCT04093388
Sites in Alabama: - Cahaba Medical Care - West End — Birmingham, Alabama
- Cahaba Medical Care - Ensley — Birmingham, Alabama
- Cahaba Medical Care — Centreville, Alabama
NA Recruiting Academic/Other
This overall objective of the RCT is to test an intervention to overcome the PA barriers for head and neck cancer (HNC) patients during the first 6 months after their treatment. PAfitME stands for a personalized Physical Activity intervent…
Sponsor: University of Alabama at Birmingham
NCT ID: NCT04632654
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama